Difference between revisions of "Programmed cell death 1"

From Libre Pathology
Jump to navigation Jump to search
Line 3: Line 3:
It is also known as '''CD279'''.  
It is also known as '''CD279'''.  


It binds with [[programmed death-ligand 1]] (dealt with separately) and ''programmed death-ligand 2''.
PD1 binds with [[programmed death-ligand 1]] (dealt with separately) and ''programmed death-ligand 2''.<ref name=pmid22658126/>
 
==Background==
Cytotoxic T cell activation is driven by three sets of receptors:<ref name=pmid22658126>{{Cite journal  | last1 = Ribas | first1 = A. | title = Tumor immunotherapy directed at PD-1. | journal = N Engl J Med | volume = 366 | issue = 26 | pages = 2517-9 | month = Jun | year = 2012 | doi = 10.1056/NEJMe1205943 | PMID = 22658126 }}</ref>
{| class="wikitable sortable"
! Pairings
! Tumour cell
! T cell
|-
| Antigen presenting
| MHC
| TCR
|-
| Inhibitory signal
| [[PD-1]]
| PD-L1 (CD274), PD-L2 (CD273)
|}


==Drugs==
==Drugs==

Revision as of 02:38, 12 May 2016

Programmed cell death 1, abbreviated PDCD1 and PD1,[1] is a protein (and gene) with an important role in immune system regulation and cancer. It is found on the T lymphocytes.

It is also known as CD279.

PD1 binds with programmed death-ligand 1 (dealt with separately) and programmed death-ligand 2.[2]

Background

Cytotoxic T cell activation is driven by three sets of receptors:[2]

Pairings Tumour cell T cell
Antigen presenting MHC TCR
Inhibitory signal PD-1 PD-L1 (CD274), PD-L2 (CD273)

Drugs

  • Pembrolizumab.
  • Nivolumab.
  • Pidilizumab.

See also

References

  1. Online 'Mendelian Inheritance in Man' (OMIM) 600244
  2. 2.0 2.1 Ribas, A. (Jun 2012). "Tumor immunotherapy directed at PD-1.". N Engl J Med 366 (26): 2517-9. doi:10.1056/NEJMe1205943. PMID 22658126.